Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies.
Shea TC, Bruner R, Wiley JM, Serody JS, Sailer S, Gabriel DA, Capel E, Moore DT, Dent G, Bentley S, Brecher ME. Shea TC, et al. Among authors: moore dt. Biol Blood Marrow Transplant. 2003 Jul;9(7):443-52. doi: 10.1016/s1083-8791(03)00204-0. Biol Blood Marrow Transplant. 2003. PMID: 12869958 Free article. Clinical Trial.
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Shea TC, et al. Among authors: moore dt. Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136. Leuk Lymphoma. 2009. PMID: 19358012 Clinical Trial.
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia.
Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, Foster MC, DeZern AE, Luznik L, Riches ML, Serody JS, Gojo I, Zeidner JF. Tschernia NP, et al. Among authors: moore dt. Transplant Cell Ther. 2021 Dec;27(12):1021.e1-1021.e5. doi: 10.1016/j.jtct.2021.08.022. Epub 2021 Aug 30. Transplant Cell Ther. 2021. PMID: 34474164 Free article. Clinical Trial.
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Zeidner JF, Vincent BG, Ivanova A, Moore D, McKinnon KP, Wilkinson AD, Mukhopadhyay R, Mazziotta F, Knaus HA, Foster MC, Coombs CC, Jamieson K, Van Deventer H, Webster JA, Prince GT, DeZern AE, Smith BD, Levis MJ, Montgomery ND, Luznik L, Serody JS, Gojo I. Zeidner JF, et al. Blood Cancer Discov. 2021 Sep 10;2(6):616-629. doi: 10.1158/2643-3230.BCD-21-0070. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778801 Free PMC article. Clinical Trial.
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, Robeson A, Kolupaev O, Cuaboy LA, Garrett AL, McKinnon K, Cowens K, Bortone D, Calhoun BC, Wilkinson AD, Carey L, Jolly T, Muss H, Reeder-Hayes K, Kaltman R, Jankowitz R, Gudena V, Olajide O, Perou C, Dees EC, Vincent BG, Serody JS. Anders CK, et al. Among authors: moore dt. J Immunother Cancer. 2022 Feb;10(2):e003427. doi: 10.1136/jitc-2021-003427. J Immunother Cancer. 2022. PMID: 35121644 Free PMC article. Clinical Trial.
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, Ibrahim JG, Bixby L, Reisdorf S, Laurie SJ, Park YA, Anders CK, Collichio FA, Muss HB, Carey LA, van Deventer HW, Dees EC, Serody JS. Vincent BG, et al. Among authors: moore dt. J Immunol. 2023 Jul 15;211(2):219-228. doi: 10.4049/jimmunol.2300077. J Immunol. 2023. PMID: 37204246 Free PMC article. Clinical Trial.
250 results